PubMed
Selank and short peptides regulate expression of inflammatory genes
Ershov et al., 2017
Neurological & CognitiveIntl. Approved (Russia)S
Selank
Tuftsin Analog TP-7
Selank is a synthetic heptapeptide anxiolytic based on the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), developed and approved in Russia for generalized anxiety disorder and as an immunomodulator. It demonstrates anxiolytic and nootropic effects comparable to benzodiazepines but without the sedation, dependence potential, or memory impairment. Administered intranasally. Not FDA-approved in the US.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- S
- Experience
- 56
- Activity
- 77
Overall check-ins
Trackers & reports
Overview
About Selank
Selank is a synthetic heptapeptide anxiolytic based on the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), developed and approved in Russia for generalized anxiety disorder and as an immunomodulator. It demonstrates anxiolytic and nootropic effects comparable to benzodiazepines but without the sedation, dependence potential, or memory impairment. Administered intranasally. Not FDA-approved in the US.
- Category
- Neurological & Cognitive
- Regulatory status
- Intl. Approved (Russia)
- Also known as
- Tuftsin Analog TP-7
- Self-reports
- 57
Community
What 57 users report
57 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
184
Recovery
184
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
94
Fatigue
85
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
3
0.2–0.4 mg
96
0.4–0.6 mg
76
0.6–1 mg
5
1–2 mg
2
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
How repeat users are trending
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 54 days · Based on 35 repeat reporters
Research
Cited research (6)
Source
PubMed
Selank, a tuftsin analogue, demonstrates anxiolytic activity
Seredenin et al., 2008
PubMed
Selank modulates immune system activity
Ershov et al., 2010
ClinicalTrials.gov
Selank studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova et al., 2020
PubMed
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Konstantinopolsky et al., 2022
Tools
Explore more
Explore
More ways to learn about Selank from observational PeptIQ data.
Help
Frequently asked
What do PeptIQ users report about Selank?
This page summarizes 57 anonymized self-reports from PeptIQ users who track Selank, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Selank?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Selank?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Selank safe to use?
This wiki does not assess safety or recommend use. Selank is listed as Intl. Approved (Russia). Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Selank?
Research, primarily in animal models, suggests Selank may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Selank?
Selank is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Selank as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Selank?
The safety and effectiveness of Selank have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Selank?
While there are over 200 published studies on Selank, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source